Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women

Fröhlich,; Schunkert,; Hense,; Tropitzsch,; Hendricks, Sharief; Döring,; Riegger,; Koenig,

doi:10.1046/j.1365-2141.1998.00594.x

Cited by 41 publications

(17 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found fibrinogen to be significantly lower among current HRT users than women who never used HRT for both diabetic and nondiabetic women. Similar findings were observed in a group of postmenopausal women aged 52-65 years (n ϭ 300), where HRT usage was associated with significantly lower fibrinogen concentration (232 vs. 268 mg/dl) and decreased plasma viscosity (29). Results from this study, however, were not provided separately for diabetic and nondiabetic women.…”

Section: Results -supporting

confidence: 76%

Hormone Replacement Therapy and Its Relationship to Lipid and Glucose Metabolism in Diabetic and Nondiabetic Postmenopausal Women

et al. 2002

View full text Add to dashboard Cite

OBJECTIVE -Among postmenopausal women, those with diabetes experience more cardiovascular diseases than those without diabetes. We examine the relationship of hormone replacement therapy (HRT) with indicators of lipid and glucose metabolism using a national sample of diabetic and nondiabetic postmenopausal women. RESEARCH DESIGN AND METHODS -We used data from the Third NationalHealth and Nutrition Examination Survey, conducted from 1988 to 1994. A total of 2,786 postmenopausal women aged 40 -74 years participated in an oral glucose tolerance test, had blood drawn for lipid assessment, and responded to HRT questions. RESULTS -Our results show that postmenopausal women with diabetes had increased dyslipidemia compared with nondiabetic women. Among diabetic women, current users of HRT had significant different lipid and glucose control levels than never users of HRT for the following variables: total cholesterol (225 vs. 241 mg/dl), non-HDL (169 vs. 188 mg/dl), apoA (171 vs. 147 mg/dl), fibrinogen (306 vs. 342 mg/dl), glucose (112 vs. 154 mg/dl), insulin (16.81 vs. 22.6 uU/ml), and GHb (6.03 vs. 7.13 mg/dl).CONCLUSIONS -Diabetic and nondiabetic postmenopausal women currently taking HRT had better lipoprotein profile than never or previous users of HRT. Diabetic women currently taking HRT had better glycemic control than never or previous users of HRT.

show abstract

Section: Results -supporting

confidence: 76%

Hormone Replacement Therapy and Its Relationship to Lipid and Glucose Metabolism in Diabetic and Nondiabetic Postmenopausal Women

et al. 2002

View full text Add to dashboard Cite

show abstract

“…In other studies, however, exogenously administered hormones were shown not to affect the levels of F 1+2 [11,13] or thrombin-antithrombin (TAT) complex [13]. These and related studies [14][15][16][17] involved measurements of procoagulant or fibrinolytic factors after administration of HRT in different dosages and formulations, in case-control studies. None of these studies addressed any association between the actual circulating levels of oestrogenic hormone(s) and haemostatic factors.…”

Section: Introductionmentioning

confidence: 99%

Correlation of Circulating 17β-Oestradiol with Haemostatic Factors in Healthy Postmenopausal Women

Mukherjee

F²,

Kadziola³

et al. 1999

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

The aim of the study was to evaluate any correlation between the circulating oestrogenic hormone 17β-oestradiol and haemostatic factors in healthy postmenopausal women. In keeping with this objective, the correlations were evaluated irrespective of whether the source of the hormone was purely endogenous or exogenous as well. Accordingly, a univariate correlation adjusted for age, body mass index, and duration of menopause was determined in 42 healthy postmenopausal women aged 47–78 years, 19 of whom were self-reported users of hormone replacement therapy. The rest were self- reported never users. Serum 17β-oestradiol exhibited a direct correlation with endogenous thrombin potential extrinsic pathway (R = 0.42, p = 0.01) and prothrombin fragments 1 and 2 (R = 0.37, p = 0.03) and an inverse correlation with antithrombin III (R = –0.36, p = 0.03) and α₂-antiplasmin (R = –0.45, p = 0.005). The observations suggest an association of this hormone with net thrombin generation on the one hand and improved fibrinolysis on the other.

show abstract

“…Also, in postmenopausal women from the S1 we found decreased plasma viscosity values during hormonal replacement therapy [12].…”

Section: Plasma Viscositymentioning

confidence: 53%

Systemic Low-Grade Inflammation and Risk of Coronary Heart Disease: Results from the MONICA/KORA Augsburg Cohort Studies

Köenig¹,

Meisinger²,

Baumert³

et al. 2005

Gesundheitswesen

View full text Add to dashboard Cite

Atherosclerosis is characterised by a non-specific local inflammatory process accompanied by a systemic response. A number of prospective studies in initially healthy subjects and in patients with manifest atherosclerosis have now convincingly demonstrated a strong and independent association between even slightly elevated concentrations of various systemic markers of inflammation (plasma viscosity, C-reactive protein [CRP], and other acute phase reactants) and a number of cardiovascular endpoints. Presently, CRP, the classical acute phase protein, seems to be the marker of choice for the clinical situation. Initial evidence suggests that measurement of CRP adds to global risk assessment based on the Framingham risk score. The recent AHA/CDC consensus report recommends the measurement of CRP in asymptomatic subjects at intermediate risk for future coronary events (10-year risk of 10 -20 %) and in selected patients after an acute coronary syndrome. Whether CRP shall alter treatment strategies in subjects without clinically manifest atherosclerosis is presently being tested in a large randomised clinical trial. In addition, recent research has suggested that CRP may not only be a risk marker, but may be directly involved in the pathogenesis of atherothrombosis. However, there are other emerging biomarkers. Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ), an enzyme produced by monocytes/macrophages, T-cells and mast cells was found to generate proinflammatory and proatherogenic molecules from oxidised LDL. We tested the association of these new biomarkers with traditional risk factors Übersicht S62This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.

show abstract

Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women

Cited by 41 publications

References 27 publications

Hormone Replacement Therapy and Its Relationship to Lipid and Glucose Metabolism in Diabetic and Nondiabetic Postmenopausal Women

Hormone Replacement Therapy and Its Relationship to Lipid and Glucose Metabolism in Diabetic and Nondiabetic Postmenopausal Women

Correlation of Circulating 17β-Oestradiol with Haemostatic Factors in Healthy Postmenopausal Women

Systemic Low-Grade Inflammation and Risk of Coronary Heart Disease: Results from the MONICA/KORA Augsburg Cohort Studies

Contact Info

Product

Resources

About